Cencora, Inc. $COR Position Boosted by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Cencora, Inc. (NYSE:COR) by 12.1% during the third quarter, Holdings Channel.com reports. The firm owned 380,804 shares of the company’s stock after buying an additional 40,985 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Cencora were worth $119,013,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Vermillion & White Wealth Management Group LLC grew its position in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after purchasing an additional 43 shares in the last quarter. Cloud Capital Management LLC purchased a new stake in Cencora in the 3rd quarter worth approximately $31,000. Westside Investment Management Inc. boosted its stake in shares of Cencora by 200.0% during the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after buying an additional 70 shares during the period. Copia Wealth Management grew its holdings in shares of Cencora by 505.0% during the 3rd quarter. Copia Wealth Management now owns 121 shares of the company’s stock valued at $38,000 after acquiring an additional 101 shares in the last quarter. Finally, Caldwell Trust Co purchased a new position in shares of Cencora during the 2nd quarter valued at $46,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of Cencora stock opened at $366.60 on Friday. The firm has a fifty day simple moving average of $351.11 and a 200-day simple moving average of $333.02. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 1-year low of $248.11 and a 1-year high of $377.54. The stock has a market capitalization of $71.31 billion, a price-to-earnings ratio of 44.06, a PEG ratio of 1.69 and a beta of 0.68.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora’s revenue was up 5.5% compared to the same quarter last year. During the same period last year, the business posted $3.73 EPS. On average, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Insider Buying and Selling

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 15,220 shares of company stock valued at $5,282,867. Insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of several recent research reports. Evercore cut their price objective on Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Barclays lifted their price target on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Wells Fargo & Company boosted their price target on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Finally, Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.